Format

Send to

Choose Destination
Trends Mol Med. 2018 Aug;24(8):682-695. doi: 10.1016/j.molmed.2018.05.008. Epub 2018 Jun 7.

APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Author information

1
Renal-Electrolyte and Hypertension Division of Department of Medicine, and Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute of Nephrology and Hypertension, Sheba Medical Center, Tel Hashomer, Israel.
2
Renal-Electrolyte and Hypertension Division of Department of Medicine, and Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: ksusztak@pennmedicine.upenn.edu.

Abstract

Chronic kidney disease (CKD) affects millions of people and constitutes a major health and financial burden worldwide. People of African descent are at an increased risk of developing kidney disease, which is mostly explained by two variants in the Apolipoprotein L1 (APOL1) gene that are found only in people of west African origin. It is hypothesized that these variants were genetically selected due to the protection they afford against African sleeping sickness, caused by the parasite Trypanosoma brucei. Targeting mutant APOL1 could have substantial therapeutic potential for treating kidney disease. In this review, we will describe the intriguing interplay between microbiology, genetics, and kidney disease as revealed in APOL1-associated kidney disease, discuss APOL1-induced cytotoxicity and its therapeutic implications.

KEYWORDS:

Apolipoprotein 1; chronic kidney disease; genetics

PMID:
29886044
PMCID:
PMC6101980
DOI:
10.1016/j.molmed.2018.05.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center